Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 536
- Registration Number
- NCT00309556
- Locations
- 🇦🇹
Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇦🇹Hospital Guessing, Guessing, Burgenland, Austria
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 429
- Registration Number
- NCT00309569
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 30
- Registration Number
- NCT00270894
- Locations
- 🇺🇸
Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Advanced Medical Specialties, Miami, Florida, United States
🇺🇸Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-02-23
- Target Recruit Count
- 82
- Registration Number
- NCT00246103
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT00242203
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT00231582
- Locations
- 🇫🇷
Hôpital TENON, Service d'Oncologie Médicale, Paris, France
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2005-09-22
- Lead Sponsor
- Department of Veterans Affairs, New Jersey
- Target Recruit Count
- 28
- Registration Number
- NCT00218205
- Locations
- 🇺🇸
Department of Veterans Affairs NJ Health Care System, East Orange, New Jersey, United States
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00215514
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 72
- Registration Number
- NCT00215644
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 3000
- Registration Number
- NCT00196872
- Locations
- 🇩🇪
Städtische Kliniken Frankfurt a.M.-Höchst, Frankfurt, Hessia, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.